Senseonics Holdings, Inc. (SENS) Q3 2025 Earnings Call Transcript
Access earnings results, analyst expectations, report, slides, earnings call, and transcript.
Overview
The earnings call highlights strong financial performance with improved gross margins and reduced net loss. The company is expanding its market presence with product launches in Europe and increased DTC marketing spend. Despite some uncertainties in timelines and payer transitions, the guidance is optimistic with expected patient growth and revenue. Positive trends in patient acquisition and competitive dynamics further support a positive outlook. The Q&A section indicates management's confidence in growth opportunities, although some details were vague. Overall, the sentiment is positive, likely leading to a stock price increase of 2% to 8%.
Key Financial Performance
Revenue Third quarter revenue grew by 90% year-over-year to $8.1 million compared to $4.3 million in the prior-year period. This growth was driven by the launch of Eversense 365 in the U.S. and increased patient adoption.
New Patient Shipments New patient shipments increased by 160% year-over-year in the third quarter. This growth was attributed to effective direct-to-consumer marketing and increased demand for Eversense 365.
Digital Campaign Leads Patient leads through digital campaigns increased by 300% year-over-year and 85% sequentially in the third quarter. This was due to meaningful investments in direct-to-consumer advertising.
New Insertions New insertions increased nearly 150% year-over-year and more than 50% sequentially in the third quarter. This reflects accelerating adoption of Eversense 365 among patients and providers.
Installed Base The installed base grew over 150% year-over-year and nearly 40% sequentially in the third quarter. This was driven by new patient starts and the adoption of Eversense 365.
Gross Profit Gross profit for the third quarter was $3.5 million, an increase of $7.5 million from the prior-year period. This improvement was due to favorable margins on the 365-day product sales and the absence of one-time charges from the prior year.
Gross Profit Margins Gross profit margins improved to over 40% in the third quarter compared to 25% at the end of 2024. This improvement was driven by the performance of Eversense 365 and operational efficiencies.
Research and Development Expenses R&D expenses decreased by $2.7 million year-over-year to $7.8 million in the third quarter. This was due to the completion of Eversense 365 system clinical trials and a reduction in headcount.
Selling, General, and Administrative Expenses SG&A expenses increased by $7 million year-over-year to $15.3 million in the third quarter. This was primarily due to higher personnel costs, promotional expenses, and sales commission expenses.
Net Loss Net loss decreased by $4.5 million year-over-year to $19.5 million in the third quarter. This improvement was driven by better gross margins and reduced R&D costs.
You have reached the limit. Sign up to access full content
Get started
Operating Highlights
Eversense 365: Achieved 90% year-over-year revenue growth in Q3 2025, driven by 160% increase in new patient shipments. Record-breaking quarter with highest new patient starts and insertions. CE mark application in Europe submitted, with approval expected by end of 2025. Planned European launch in H1 2026.
Gemini and Freedom pipeline products: IDE for Gemini on track for submission in Q4 2025, with U.S. approval expected in late 2026. IDE for Freedom to be filed in H2 2026, targeting commercial launch by early 2028.
Direct-to-Consumer (DTC) Marketing: Investments led to a 300% year-over-year and 85% sequential increase in patient leads. 60% of new patients in Q3 originated from DTC advertising. Social media campaigns are a key focus.
European Market Expansion: Transitioning commercialization from Ascensia to Senseonics' own sales force. European CGM employees to transition in Q1 2026. Distribution agreements being finalized.
Operational Integration: Reassumed control of Eversense commercialization from Ascensia. Transition to be completed by January 1, 2026, in the U.S. and H1 2026 in Europe. CRM and ERP systems expanded to support this.
Eon Care Network: Expanded insertion capacity, now representing 25% of all insertions nationwide. Added 75 new trained inserters in Q3 2025, a 140% year-over-year increase.
Insulin Pump Integration: Sequel's twiist insulin delivery system to integrate with Eversense 365, enabling closed-loop system. Expected to drive growth in 2026.
Margin Expansion: Gross profit margins improved to over 40% in Q3 2025, projected to reach 50% in 2026 and 70% at scale.
You have reached the limit. Sign up to access full content
Get started
Risk or Challenges
Regulatory Approval Delays: The CE mark application for Eversense 365 in Europe is still under review, with approval expected by the end of 2025. Any delays in this process could impact the planned launch in the first half of 2026 and subsequent revenue growth.
Transition Risks with Ascensia: The transition of commercialization efforts from Ascensia Diabetes Care to Senseonics involves setting up new infrastructure, transferring employees, and finalizing agreements. Any missteps in this process could disrupt operations and impact sales.
Supply Chain and Tariff Challenges: The company is monitoring the impact of tariffs and supply chain issues, which could negatively affect margins if not mitigated effectively.
High Cash Utilization: The company expects cash utilization of approximately $60 million in 2025, which could strain financial resources if revenue growth or cost management does not meet expectations.
Dependence on DTC Marketing: The company’s growth heavily relies on direct-to-consumer (DTC) marketing investments. Any reduction in the effectiveness of these campaigns could slow patient acquisition and revenue growth.
Integration with Sequel's Twiist Pump: The integration of Eversense 365 with Sequel's Twiist insulin pump is a key growth driver for 2026. Delays or technical challenges in this integration could impact future revenue.
Revenue Recognition Changes: The transition from Ascensia's distribution model to Senseonics' direct model will eliminate revenue sharing but could introduce complexities in revenue recognition and financial reporting.
Economic and Market Conditions: Economic uncertainties and market conditions could impact patient adoption rates, especially given the high reliance on DTC marketing and out-of-pocket costs for patients.
You have reached the limit. Sign up to access full content
Get started
Guidance & Outlook
Revenue Expectations: The company expects full year 2025 global net revenue to be approximately $35 million, with the majority of revenue in the fourth quarter due to continued momentum in new patient starts and reorders from the first U.S. 365 patients.
Margin Projections: Gross profit margins are expected to be between 35% and 40% for 2025, with projections to exceed 50% in 2026 and reach approximately 70% at scale for the unified business.
Market Trends and Growth Expectations: The company anticipates doubling the global patient base in 2025 compared to 2024. Significant new patient additions and top-line growth are expected due to expanding awareness and adoption of Eversense 365 in the U.S.
Product Launches and Approvals: The CE mark approval for Eversense 365 in Europe is expected by the end of 2025, with a planned launch in the first half of 2026. The IDE for Gemini is on track to be submitted in Q4 2025, with U.S. approval planned for late 2026. The IDE for Freedom is expected to be filed in the second half of 2026, targeting a commercial launch by early 2028.
Strategic Partnerships: The company is working with Sequel to integrate Eversense 365 with the twiist insulin delivery system, targeting a launch in 2026. Additional announcements on insulin pump integrations are expected in the coming quarters.
Operational Changes: The transition of Eversense commercialization from Ascensia Diabetes Care to Senseonics is expected to be completed by January 1, 2026, in the U.S., and during the first half of 2026 in Europe. This transition is anticipated to positively impact margins and operational efficiency.
You have reached the limit. Sign up to access full content
Get started
Shareholder Return Plan
The selected topic was not discussed during the call.
You have reached the limit. Sign up to access full content
Get started
Key Q&A
Q:Can you provide insights into the growth opportunities in DTC and the source of new patient implants?
A:The growth in DTC is geographically well-distributed, focusing on high-prescribing, best reimbursement, and high insulin utilization areas. Significant growth is seen in switchers, with 90% of new patients coming from existing CGM users (60-65% from Dexcom and 35-40% from Libre). Two-thirds of patients are from commercial pay, with the rest from Medicare.
Q:What is the timeline and expected contribution of the integration with twiist and Sequel?
A:The integration is expected to contribute in 2026. Early launch activities are ongoing, with the first patients expected in Q1 2026. Initial ramp-up may be limited by pump availability, but expansion is anticipated later in the year, especially in the second half.
Q:How do you envision the inserter network evolving outside of Eon, and what is the impact of Medicare reimbursement?
A:The Eon network supports primary care expansion. Some clinicians institutionalize the insertion process, while others refer to Eon nurses. Medicare reimbursement and CPT codes are attractive incentives for providers, leading to growth in institutionalized insertion processes.
Q:What is the update on private payers adopting bundled payment reimbursement, and what is the mix between endos and PCPs?
A:Private payers are transitioning to bundled payment reimbursement, with United being a major adopter. Kaiser is expected to follow by 2026. The mix is more heavily weighted towards endos, but PCPs are growing, especially with Medicare expansion.
Q:What is the plan for DTC push and SG&A commitment in 2026?
A:The DTC investment in 2026 will be consistent with 2025 levels, adjusted for buying patterns. The fourth quarter is expected to see the largest investment due to new deductibles and medical equipment purchases.
Q:Can you provide insights into new patient starts and competitive dynamics in the CGM space?
A:New patient starts were at record levels in Q3 and September, with strong trends continuing in October. Competitive dynamics show increased awareness and preference for Eversense due to its features like duration and accuracy. Basal-only patients, especially Medicare ones, are a growing segment.
Q:What is the revenue guidance for 2025 and the impact of inventory dynamics on 2026?
A:The revenue guidance for 2025 is $35 million, slightly refined from the previous $34-38 million range. Inventory dynamics during the transition from Ascensia to Senseonics will impact 2026 revenue, with a reduction in channel inventory.
Q:What is the update on the CE mark for Eversense 365 and the European transition process?
A:The CE mark for Eversense 365 is expected in Q4 2025. The European transition involves setting up entities, transitioning CGM-dedicated employees, and hiring a new sales force. The 365-day product will launch in the first half of 2026 with the new sales force.
Q:What is the timeline for the Freedom product and its commercial contribution?
A:The Freedom product is expected to receive approval in Q4 2027, with commercial contributions beginning in 2028.
Q:What is the effectiveness of DTC marketing spend and its impact on patient acquisition?
A:DTC marketing spend directly increases patient acquisition. Targeted and geo-specific advertising is more effective, while broad advertising reaches less relevant audiences. The Eon network supports DTC efforts, with plans to double the number of Eon nurses to 100 in 2026.
Q:Review of Unclear Management Responses
A:Management avoided providing exact numbers for the mix between endos and PCPs, stating they would get back with the data. They also did not provide specific details on the private payer transition timeline beyond general expectations for 2026. Additionally, the CE mark timeline for Eversense 365 was described as unpredictable, with no specific reasons for the delay provided.
You have reached the limit. Sign up to access full content
Get started
Earnings Word Cloud
The most frequently occurring keywords in this quarter's earning call
ADC
Ascensia CGM
Ascensia transition
CGM Senseonics
CRM system
DTC advertising
DTC investment
Eon Care
Eon capacity
Eversense Senseonics
HCP
Mr
accounting adjustment
agreement transition
balance
channel mix
commercialization
demand patient
driver
employee
enabler
favorability
inserter
inserters
insulin delivery
integration quarter
inventory Senseonics
investor
loop system
margin improvement
number patient
patient Eon
patient provider
referral
reinsertion
reorder
sale force
split
track
transition Ascensia
SENS Transcript
Senseonics Holdings, Inc. (SENS) Q1 2026 Earnings Call Transcript
Unknown5-8
The earnings call presents mixed signals: while there are positive aspects such as increased revenues, strong retention rates, and seamless transitions, these are counterbalanced by increased expenses, net losses, and vague guidance on partnerships. The Q&A section highlights concerns over partnership timelines and cost efficiencies. The lack of clear guidance and the increase in expenses and net loss weigh down the overall sentiment, leading to a neutral prediction for the stock price movement over the next two weeks.
Senseonics Holdings, Inc. (SENS) Q4 2025 Earnings Call Transcript
Positive3-2
The earnings call summary shows a positive sentiment with a 20% revenue increase and improved gross margins. Despite a net loss, it has narrowed significantly, indicating better cost management. The strategic plan outlines growth expectations and new product launches, which are promising. The lack of clear management responses in the Q&A is a concern but not enough to offset the positive financials and strategic outlook. Overall, the sentiment is positive, anticipating a stock price increase of 2% to 8%.
Senseonics Holdings, Inc. (SENS) Q3 2025 Earnings Call Transcript
Positive11-5
The earnings call highlights strong financial performance with improved gross margins and reduced net loss. The company is expanding its market presence with product launches in Europe and increased DTC marketing spend. Despite some uncertainties in timelines and payer transitions, the guidance is optimistic with expected patient growth and revenue. Positive trends in patient acquisition and competitive dynamics further support a positive outlook. The Q&A section indicates management's confidence in growth opportunities, although some details were vague. Overall, the sentiment is positive, likely leading to a stock price increase of 2% to 8%.
Senseonics Holdings, Inc. (SENS) Q2 2025 Earnings Call Transcript
Positive8-6
The earnings call shows strong financial performance with a 37% increase in net revenue and improved gross profit margins. Despite a net loss, the company reduced R&D expenses and increased cash position through public offerings. The Q&A section highlights positive retention rates and potential growth from the consignment program and Eon Care. However, there are uncertainties in retention data for the 365 version and revenue impact from Eon Care. Overall, the financial results and strategic initiatives suggest a positive stock price movement in the short term.
SENS Report
Frequently Asked Questions
Where does this earnings call transcript come from?
All transcripts are sourced directly from the official live webcast or the company’s official investor relations website. We use the exact words spoken during the call with no paraphrasing of the core discussion.
How soon is the transcript available after the earnings call ends?
Full verbatim transcripts are typically published within 4–12 hours after the call ends. Same-day availability is guaranteed for all S&P 500 and most mid-cap companies.
Is the transcript edited or altered in any way?
No material content is ever changed or summarized in the “Full Transcript” section. We only correct obvious spoken typos (e.g., “um”, “ah”, repeated 10 times”, or clear misspoken ticker symbols) and add speaker names/titles for readability. Every substantive sentence remains 100% as spoken.
Why do some answers appear as “Unclear” or “Inaudible”?
When audio quality is poor or multiple speakers talk over each other, we mark the section instead of guessing. This ensures complete accuracy rather than introducing potential errors.
Who creates the AI Summary and Key Q&A highlights shown above the transcript?
They are generated by a specialized financial-language model trained exclusively on 15+ years of earnings transcripts. The model extracts financial figures, guidance, and tone with 97%+ accuracy and is regularly validated against human analysts. The full raw transcript always remains available for verification.
